Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
Prof. Pavel Poredos,
There exists a close relationship between peripheral arterial occlusive disease (PAOD) and carotid atherosclerosis, including preclinical lesions (increased intima-media thickness – IMT and non-stenotic plaques). The association was confirmed also between ankle-brachial pressure index (ABI) and IMT. Lower values of ABI are independently of risk factors related to the carotid atherosclerosis.
Atherosclerosis is considered to be a systemic disease. Therefore, patients with a clinical manifestation of a particular atherosclerotic disease are likely to have atherosclerotic lesions in other vascular beds. Epidemiological and clinical studies have shown that peripheral arterial occlusive disease (PAOD) is a common disorder associated with the presence of coronary (CHD) or cerebrovascular disease (CVD) and a profoundly increased risk of cardiovascular and cerebrovascular events and mortality (1,2). It was also shown that not only clinical but also the preclinical stages of PAOD, represented by a borderline decrease of the ankle-brachial index (ABI), have a strong predictive value and that the risk of cardiovascular mortality increases with the severity of PAOD (3,4).
Easy accessibility enables to use peripheral arteries as surrogate markers of cerebrovacular and systemic atherosclerosis. Moreover, for detection of PAOB a simple and reliable diagnostic techiques are available. Especially, ABI is a very useful, diagnostic (and risk assessment) tool that also predicts carotid atherosclerosis.
Interrelationship between peripheral arterial occlusive disease and carotid atherosclerosis was confirmed in different studies. House and co-workers reported that 35 % of the patients with peripheral arterial occlusive disease have in internal carotid stenosis (ICAS) greater that 50 %. Males presented associated carotid stenosis at a younger age than females and in females the greatest prevalence of internal carotid artery stenosis was associated with abdominal aortic aneurism (5). The SMART Study (Second Manifestation of ARTerial disease) showed that in PAOD patients ICAS is present in 14 % and that the prevalence of ICAS increased to as much as 50% in patients who had additional risk indicators (age 67 years, pulse pressure 74 mmHg, ABI 0.78) (6). Not only symptomatic, but also asymptomatic PAOD (ABI ≤ 0.9) is related to the higher prevalence of cerebrovascular disease. In the Limburg – PAOD study the prevalence of CVD in asymptomatic PAOD patients was even two times higher than in symptomatic (7). Increased morbidity, caused by simultaneous presence of PAOD and carotid atherosclerosis results in increased mortality. Cricqui with co-workers showed that the mortality because of CVD in PAOD patients was 2.5 times as great as in those without PAOD (2).
Mostly used indicator of the presence and severity of PAOD is ABI. Irrespective if the PAOD disease is symptomatic or asymptomatic, decreased ABI represents an increased risk for cardiovascular, including cerebrovascular incidents. ARIC Study showed inverse linear trend between ABI and ischemic stroke incidence. The lowest ABI group (≤ 0.80) had a risk ratio of 5.68 for CVD and it was shown that there also exists an interrelationship between ABI and preclinical carotid atherosclerosis – intima media thickness (IMT). Individuals with decreased ABI (≤ 0.9) had significantly greater carotid IMT and were twice as likely to have preclinical plaques than those with normal ABI (3). Similarly, the Rotterdam Study showed significant inverse association between common carotid artery IMT and ABI. The calculations showed that an increase of IMT for 0.1 mm is associated with reduction of ABI of 0.026. This study also showed that the prevalence of symptomatic and asymptomatic PAOD is strongly increased among subjects with IMT > 0.89 mm (8). Therefore, low ABI reflects not only clinical, but also preclinical atherosclerotic lesions in carotid arteries.
In one of our studies we investigated morphological characteristics of carotid arteries in PAOD patients in comparison to healthy subjects. It was shown that only 7 % of patients had normal morphological characteristics of carotid arteries (including IMT), 23 % of them had increased intima-media thickness and in 70 % atherosclerotic plaques were detected. In healthy subjects IMT was increased in only 15 % and atherosclerotic plaques were found in 8 %. Further, a close interrelationship between ABI and PAOD and between ABI and number of atherosclerotic plaques on carotid arteries was found (9). However, these results arose the question if low ABI would add substantial prognostic ability beyond determination of traditional risk factors of atherosclerosis. In the ARIC Study it was shown that after adjustment for other risk factors of stroke (age, gender, blood pressure and fibrinogen) the relation between ankle-brachial pressure index and incidence of cerebrovascular disease was substantially reduced and was not more significant. However, in our study the association of ABI with IMT and carotid plaques retained statistical significance even after adjustment for risk factors of atherosclerosis. Therefore we concluded that lower values of ABI (0.34 - 0.82) charasteristic for0 symptomatic PAOD patients (claudicants) are (independently of risk factors for atherosclerosis related) to intima-media thickness of carotid arteries.
Determination of ABI improves identification of subjects at high risk of cardiovascular (including cerebrovascular) events, especially in asymptomatic patients. Since asymptomatic PAOD patients are at very high risk for an ischemic event (like the patients with multifocal symptomatic disease), they deserve special interventive effort and are likely to experience the greatest profit of risk reduction procedures. Therefore, in some populations determination of ABI has additional prognostic value beyond traditional risk factor identification.
The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.
1. Clement DL, Boccalon H, Dormandy J, Durand-Zaleski I, Fowkes G, Brown T. A clinical approach to the management of the patients with coronary (Co) and/or carotid (Ca) artery disease who presents with leg ischemia (Lis). Int Angiol 2000; 19: 97-125. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10905794&dopt=Abstract
2. Criqui MH, Denenberg JO. The generalized nature of atherosclerosis: how peripheral arterial disease may predict adverse events from coronary artery disease. Vasc Med 1998; 3: 241-5. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9892517&dopt=Abstract
3. Zheng ZJ, Sharrett AR, Chambless LE, Rosamond WD, Nieto FR, Sheps DS et al. Associations of ankle-brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis; the Atherosclerosis Risk in Communities (ARIC) study. Atherosclersois 1997; 131: 115-25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9180252&dopt=Abstract
4. Long TH, Criqui MH, Vasilevskis EE, Denenberg JO, Klauber MR, Fronek A. The correlation between the severity of peripheral arterial diseases and carotid occlusive disease. Vasc Med 1999; 4: 135-42. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10512592&dopt=Abstract
5. House AK, Bell R, House J, Mastaglia F, Kumart A, DAntuono M. Asymptomatic carotid artery stenosis associated with peripheral vascular disease: a prospective study. Cardiovasc Surg 1999; 7: 44-9. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10073759&dopt=Abstract
6. Simons PCG, Algra A, Eikelboom BC, Grobbee DE, van der Graaf Y for the SMART study group. Carotid artery stenosis in patients with peripheral arterial disease: The SMART. J Vasc Surg 1999; 30: 519-25. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10477645&dopt=Abstract
7. Hooi JD, Stoffers HEJH, Kester ADM, Rinkens PELM, Kaiser V, van Ree JW, Knottnerus JA. Risk factors and cardiovascular disease associated with asymptomatic peripheral arterial occlusive disease. The Limburg PAOD Study. Scand J Prim Health Care 1998; 16: 177-82. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=9800232&dopt=Abstract
8. Bots Ml, Hofman A, Grobbee DE. Common carotid intima-media thickness and lower extremity arterial atherosclerosis. Arterioscler Thromb 1994; 14: 1885-91. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=7981175&dopt=Abstract
9. Poredoš P, Golob M, Jensterle M. Interrelationship between peripheral arterial occlusive disease, carotid atherosclerosis and flow mediated dilation of the brachial artery. Int Angiol 2003; 22: 83-7. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12771862&dopt=Abstract
Prof. P. Poredos Ljubljana, Slovenia Vice-chair of the ESC Working Group on Peripheral Circulation.
Our mission: To reduce the burden of cardiovascular disease
© 2017 European Society of Cardiology. All rights reserved